Paul E. Goss, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, discusses disease-free survival results from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA1).
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts 5001, 5003, 5023, and 5021).
Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advanced/metastatic disease (Abstract LBA4500).
Alan Venook, MD, of the University of California, San Francisco, and John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, discuss the impact of primary tumor location on overall survival and progression-free survival in patients with advanced disease (Abstract 3504).
Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Heather A. Wakelee, MD, of Stanford University, discuss findings on adjuvant chemotherapy with or without bevacizumab for early-stage non–small cell lung cancer, with outcomes based on chemotherapy subsets (Abstract 8507).
Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.
